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Abstract
Background: The UICC/AJCC TNM staging system classifies lymph nodes as N0 and N1 in pancreatic cancer. Aim
of the study is to determine whether the number of examine nodes, the nodal ratio (NR) and the logarithm odds
of positive lymph nodes (LODDS) may better stratify the prognosis of patients undergoing pancreatectomy
combined with venous resection for pancreatic cancer with venous involvement.
Methods: A multicenter database of 303 patients undergoing pancreatectomy in 9 Italian referral centers was
analyzed. The prognostic impact of number of retrieved and examined nodes, NR, LODDS was analyzed and
compared with ROC curves analysis, Pearson test, univariate and multivariate analysis.
Results: The number of metastatic nodes, pN, the NR and LODDS was significantly correlated with survival at
multivariate analyses. The corresponding AUC for the number of metastatic nodes, pN, the NR and LODDS were
0.66, 0.69, 0.63 and 0.65, respectively. The Pearson test showed a significant correlation between the number of
retrieved lymph nodes and number of metastatic nodes, pN and the NR. LODDS had the lower coefficient
correlation. Concerning N1 patients, the NR, the LODDS and the number of metastatic nodes were able to
significantly further stratify survival (p = 0.040; p = 0.046; p = 0.038, respectively).
Conclusions: The number of examined lymph nodes, the NR and LODDS are useful for further prognostic
stratification of N1 patients in the setting of pancreatectomy combined with PV/SMV resection. No superiority
of one over the others methods was detected.
Keywords: Pancreatic cancer, Tnm, Nodal ratio, Lodds, Prognosis, Nodal staging, Venous invasion, Portal vein,
Superior mesenteric vein, Pancreatectomy
Background
Pancreatic cancer represents the fourth-leading cause of
cancer-related mortality in the United States with an es-
timated 53,670 new cases in 2017 and 43,090 deaths [1].
In Europe, an estimated 103,773 new cases were re-
ported in 2012 [2]. Lymph nodal status is an important
prognostic factor in these patients, as a determinant for
the appropriate prognostic stratification and therapeutic
decision-making [3]. Patients with pancreatic carcinoma
with portal vein (PV) and/or superior mesenteric vein
(SMV) invasion represent a particular challenge regard-
ing prognostic analysis and treatment. The seventh edi-
tion of the International Union against Cancer (UICC)
and the American Joint Committee on Cancer (AJCC)
Tumor Node Metastasis (TNM) staging system classify
regional lymph nodes as N0 and N1, according to the
presence of none or one or more nodal metastases [4].
The number of lymph nodes should be reported because
it represents a prognostic factor, and N0 patients have a
better prognosis with an increasing number of examined
lymph nodes [5–8]. For optimal staging, the analysis of
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11–17 lymph nodes is recommended [5–9]. However,
extended lymphadenectomy does not provide a sur-
vival advantage, according to randomized trials and
meta-analyses [10–13]. In light of these data, the
International Study Group of Pancreatic Surgery
(ISGPS) agreed on a definition of standard lymphade-
nectomy [14]. Inaccurate surgical dissection, patho-
logical evaluation or both may cause understaging for
the suboptimal number of analyzed nodes, and subse-
quent inappropriate prognostic evaluation and error
in clinical decisions [15].
To optimize nodal staging in patients with pancreatic
cancer, different systems have been proposed and
studied. The nodal ratio (NR) (ratio between metastatic
and retrieved nodes) permits a subclassification of N1
patients, but it does not provide more information than
TNM for N0 patients. Several authors have shown that
the NR is a significant prognostic factor for overall
survival [16, 17]. LODDS (log odds of positive lymph
nodes), defined as the logarithm of the ratio between the
number of positive nodes and number of negative nodes,
has thus been proposed as more effective than the NR in
N0 patients [15].
Until now, few studies have compared all nodal staging
systems in patients with pancreatic carcinoma and no
data have been published on patients with PV/SMV ven-
ous invasion. Therefore, our aim is to analyze and com-
pare different nodal staging systems in a subgroup of
patients who underwent pancreatectomy with combined
venous resection in nine Italian referral centers in order
to identify the more advantageous nodal classification in
this subset of patients.
Methods
The study included 303 patients who underwent pan-
createctomy combined with PV or SMV resection for
pancreatic carcinoma. The procedures were performed
at nine Italian referral institutions. Some data
retrieved from this multicenter database have already
been published [18]. Written informed consent for
participation in the study was obtained from
participants.
Preoperative work-up and surgical treatment
The diagnosis of pancreatic adenocarcinoma was con-
firmed by pathological examination in all cases. Regard-
ing neoadjuvant treatment, the multidisciplinary board
of each unit established the indication and protocol,
after imaging discussion among radiologists and
clinicians.
Pancreaticoduodenectomy, left spleno-pancreatectomy
or total pancreatectomy were performed according to
the site of the lesion. Lymphadenectomy was performed
as previously described in a standard fashion [14].
Definition of clinical outcomes and pathological
examination
Postoperative mortality was defined as death during
hospitalization or during the the first 30 days after
pancreatectomy. For postoperative complications,
ISGPS definitions were used [19, 20]. The presence of
tumor cells within 1 mm from the margin was
defined as R1 resection. Evidence of macroscopic re-
sidual tumor was defined as R2. ISGPS recommenda-
tions were followed [21].
Lymph nodal staging systems
N status was defined according to the AJCC staging sys-
tem. The nodal ratio (NR) was defined as the ratio be-
tween the number of positive nodes and total harvested
nodes. The classification system validated by Malleo et
al. was chose for NR, after a careful review of the litera-
ture. Interval values were as follows: 0, 0.01–0.2, 0.21–
0.4 and more than 0.4 [3]. LODDS were calculated by
log (pnod + 0.5)/(tnod-pnod + 0.5), where pnod was the
number of positive lymph nodes and tnod was the total
number of examined nodes; 0.5 was added to both the
numerator and the denominator to avoid an infinite
number [15]. Patients were divided into two groups, di-
chotomizing the LODDS values around the median
value. Each subgroup was further divided into two, di-
chotomizing again around the median LODDS value,
resulting in four LODDS groups. The classification re-
ported by Strobel et al. was chosen for the number of
positive nodes, [8].
Adjuvant therapies and follow-up
The multidisciplinary tumor board of each institution
validated the indication for adjuvant chemotherapy or
radiochemotherapy. Decision was based on patients’ per-
formance status and pathological results. During follow-
up, physical examination and CA 19–9 determination
were scheduled every 3 months in the first 2 years and
than every 6 months, and thoraco-abdominal CT scan
every 6 months in the first 2 years.
Statistical analysis
The multicenter database was prospectively collected by
each center and retrospectively analyzed. T-test for con-
tinuous variables and the chi-square test for categorical
variables were used to calculate differences in distribu-
tion. Overall survival rates were calculated according to
the Kaplan–Meier method, and we used the log-rank
test to assess the statistical differences between different
groups. Univariate and multivariate analyses were used
to identify the most significant. Correlation between
nodal staging systems and prognosis was assessed with
univariate and multivariate analyses. Variables significant
in the univariate analysis were used for the multivariate
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model, analyzing separately each nodal staging system.
Overall survival rates were calculated according to dif-
ferent pN, NR, LODDS, number of metastatic nodes and
number of retrieved nodes. ROC curves analysis was
used to evaluate the accuracy of the different nodal sta-
ging systems, using nodal classifications as variables and
5-year survival as classification variables. The method of
Delong et al. [22] was used. Pearson correlation coeffi-
cient was used to calculate the correlations between
number of retrieved nodes, number of metastatic nodes,
NR and LODDS. p < 0.05 was considered as statistically
significant. Statistical analyses were performed by using
MedCalc for Windows, version 10.2.0.0 (MedCalc
Software, Belgium).
Results
Patients’ characteristics, preoperative work-up and treat-
ment and surgery
The study population was composed of 165 men (54.5%)
and 138 women (45.5%). The majority of patients were
classed as N1 (70.6%). Patients’ characteristics according
to nodal status are listed in Table 1. One hundred and
eighty-seven patients (61.7%) had one or more comor-
bidity. Cardiovascular comorbidities were detected in
49.5% of patients, respiratory comorbidities in 12.2% and
metabolic comorbidities in 29.0%.
Mean tumor diameter according to the CT scan was
32.9 ± 15.4 mm. Preoperative biliary drainage was
performed in 28.6% of cases, and neoadjuvant chemo-
therapy was administered to 6.4% of patients.
The majority of patients underwent pancreaticoduode-
nectomy (PD) (76.9%), 60 (19.8%) underwent left
pancreatectomy (LP) and 10 (3.3%) total pancreatectomy
(TP) (Table 1). All patients underwent portal or superior
mesenteric vein resection. Mean operative time was
462.6 ± 134.2 min and blood loss 475.2 ± 401.6 ml.
Postoperative outcomes, pathological and lymph nodal
analysis and survival
Complications occurred in 49.8% of patients and mortal-
ity in 6.6% (Table 2). Postoperative pancreatic fistula oc-
curred in 11.9% and delayed gastric emptying in 23.1%.
Mean intensive care unit stay was 3.2 ± 4.6 days. Mean
hospital stay was 20.4 ± 11.6 days. Histological venous
invasion was found in 53.8% of venous specimens. Mean
tumor diameter was 35.0 ± 20.7 mm. The mean number
of retrieved lymph nodes was 33.5 ± 22.6 and ranged
from 2 to 131. The mean number of metastatic nodes
was 3.4 ± 4.5, ranging from 0 to 25. Patients undergoing
LP had a significantly higher number of retrieved lymph
nodes than patients undergoing PD (47.9 ± 25 versus
29.6 ± 20.2; p < 0.0001). The mean number of metastatic
nodes was not different in patients submitted to PD (3.1
± 4), LP (4.4 ± 5.8) and TP (3.7 ± 4.9). The resection mar-
gin was tumor-free in 73.3% of cases. Adjuvant therapy
was administered to 72.1% of patients. Mean follow-up
duration was 37.9 months. Median overall survival was
25 months and five-year survival rate was 25.2%.
Analysis of prognostic factors
Table 3 shows survival according to patient and tumor
characteristics. Factors that significantly correlated with
overall survival were the number of metastatic nodes,
pN, the NR and LODDS, whereas no correlation was
Table 1 Patients’ characteristics and procedures. Data are presented for the entire cohort and according to nodal status. Continuous
variables are presented as mean ± SD
Variable N0 (89) N1 (214) Total (303) p
Age 65.7 ± 10.7 67.4 ± 10.5 66.9 ± 10.6 0.223
Sex, Females 40.7% 47.5% 45.5% 0.348
ASA score 2.3 ± 0.7 2.5 ± 0.7 2.4 ± 0.7 0.379
BMI 23.8 ± 2.9 24.1 ± 3.2 24.0 ± 3.1 0.651
Comorbidities 57.0% 63.5% 61.7% 0.381
CEA (UI/ml) 15.7 ± 33.7 10.7 ± 19.1 12.0 ± 23.6 0.452
CA 19.9 (UI/ml) 592 ± 1276 644 ± 1375 637.0 ± 1345 0.831
Albumin (g/dl) 3.8 ± 0.6 3.7 ± 0.6 3.7 ± 0.6 0.258
Bilirubin (mg/dl) 6.7 ± 15.7 6.2 ± 6.3 6.3 ± 9.7 0.745
Tumor diameter at CT, mm 36.3 ± 22.6 31.6 ± 11.7 32.9 ± 15.4 0.103
Surgery 0.747
PD, number 68 165 233
LP, number 18 42 60
TP, number 3 7 10
SD standard deviation, ASA American Society of Anesthesiology, BMI Body Mass Index, CEA carcinoembryonic antigen, CA 19.9 Carbohydrate Antigen 19.9, CT
computed tomography, PD pancreaticoduodenectomy, LP left pancreatectomy, TP total pancreatectomy
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found for age, sex, comorbidities, tumor size, number
of retrieved nodes, T stage and resection margin.
Figs. 1, 2, 3 and 4 show the survival curves according
to the number of metastatic nodes, pN, the NR and
LODDS, respectively. According to the multivariate
analyses, the number of metastatic nodes, pN, the NR
and LODDS were significantly correlated with survival
(Table 4).
Comparison between pN staging, the NR and LODDS
methods
The corresponding AUC for the number of metastatic
nodes, pN, the NR and LODDS were 0.66 (95% CI 0.58
to 0.73), 0.69 (95% CI 0.62 to 0.76), 0.63 (95% CI 0.55 to
0.70) and 0.65 (95% CI 0.57 to 0.72), respectively, with
no significant differences (Fig. 5). The scatter plot of the
relationship between LODDS and the NR is reported in
Fig. 6. The LODDS value increased with the ratio of
metastatic lymph nodes, showing correlation between
LODDS and the NR. Values of LODDS were still hetero-
geneous, even in cases with NR = 0. A significant
correlation between the number of retrieved lymph
nodes and number of metastatic nodes was found at
Pearson test (Table 5). The correlation values were lower
for pN and the NR, and LODDS had the lower
Table 2 Postoperative complications and mortality in 303
patients submitted to pancreatectomy with portal vein and/or
superior mesenteric vein resection
Variable N. %
Overall complications 151 49.8%
Mortality 20 6.6%
Pancreatic fistula 36 11.9%
Grade A 16
Grade B 14
Grade C 6
DGE 70 23.1%
Grade A 32
Grade B 25
Grade C 13
Non pancreatic leak 9 3.0%
Postoperative bleeding 18 5.9%
Re-laparotomy 21 6.9%
PV-SMV thrombosis 5 1.7%
Abdominal collection 33 10.9%
Need of postoperative abdominal
drain
36 11.9%
Wound infection 16 5.3%
Urinary tract infection 3 1.0%
Cardiovascular complications 6 2.0%
DVT/PE 5 1.6%
Acute renal failure 3 1.0%
Pneumonia 4 1.3%
N number, DGE delayed gastric emptying, PV-SMV portal vein-superior
mesenteric vein, DVT/PE deep venous thrombosis/pulmonary embolism
Table 3 Clinicopathological data and univariate survival analysis
results of 303 patients submitted to pancreatectomy with portal
vein and/or superior mesenteric vein resection
Variable Patients (%) Median survival
(months)
p (univariate
analysis)
Age 0.531
< 70 53.2 28.3
≥ 70 46.8 24
Sex 0.094
Males 54.5 25
Females 45.5 26
Comorbidities 0.058
No 38.3 26
Yes 61.7 24
Tumor size 0.193
<30 mm 37.3 28
≥30 mm 62.7 24
Resection margin 0.850
R0 73.3 27
R1 26.7 23
T stage 0.506
1 0.7 na
2 6.6 28
3 86.1 24
4 6.6 22
Number of retrieved
lymph nodes
0.797
< 17 24.1 26
≥ 17 75.9 24
Number of metastatic
lymph nodes
0.0005
0–2 56.1 35
≥ 3 43.9 22
N stage 0.0002
N0 29.4 46
N1 70.6 23
NR 0.0005
0 29.4 43
0.01–0.2 48.2 24
0.21–0.4 16.2 17
> 0.4 6.3 22
LODDS 0.0013
Lodds <−0.005 23.4 72
−0.005 ≤ Lodds <0.012 24.8 32
0.012 ≤ Lodds <0.026 26.1 22
Lodds ≥0.026 25.7 22
NR nodal ratio, LODDS log odds of positive lymph nodes
Ramacciato et al. BMC Surgery  (2017) 17:109 Page 4 of 9
coefficient correlation (0.079) with the number of re-
trieved nodes (p = 0.154).
Further stratification of N1 and N0 patients
Concerning N1 patients, the NR was able to further
stratify survival, with patients with NR < 0.2 having bet-
ter prognosis (median survival of 24 versus 19 months,
p = 0.040). Further, LODDS stratified N1 patients into
two groups with different prognoses, with patients of
LODDS >0.03 having significantly worse survival (20
versus 24 months, p = 0.046). In addition, the number of
metastatic nodes was able to stratify N1 patients in this
series, according to the classification reported by Strobel
et al. (p = 0.038). In the group of patients with <17 re-
trieved lymph nodes, pN, the NR and LODDS were
all able to stratify patient survival (p = 0.01, p = 0.023
and p = 0.05, respectively). The LODDS classification
was used to stratify the 89 N0 patients; LODDS1
patients had a median survival of 72 months, whereas
LODDS2 patients had a median survival of 36 months
(not statistically significant; p = 0.229).
Discussion
Lymph nodal status is considered to be one of the most
important prognostic factors after pancreatectomy for
adenocarcinoma. The most used nodal staging system is
the N status of the AJCC classification, which identifies
N0 and N1 patients, according to the presence or
absence of nodal metastases. Previous studies have
analyzed the prognostic role of the number of examined
lymph nodes, number of pathologic lymph nodes, the
NR and LODDS in patients with pancreatic cancer, with
different results [5, 6, 8, 23, 24]. The number of positive
nodes has been suggested to stratify N1 patients, adding
prognostic information [8, 25]. Strobel and colleagues
reported a median survival of 31.1, 26.1, 21.9 and
18.3 months in patients with 1, 2–3, 4–7 and >7 positive
nodes, respectively [8]. The role of the number of posi-
tive nodes was also shown in patients submitted to
Fig. 1 Overall survival according to the number of metastatic nodes
Fig. 2 Overall survival according to pN status
Fig. 3 Overall survival according to the NR
Fig. 4 Overall survival according to LODDS
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pancreatic surgery after neoadjuvant therapy [25].
Concerning the NR, a number of authors have dem-
onstrated its ability to further stratify node-positive
patients [26, 27].
LODDS are new prognostic parameters, which aim to
better stratify patients regarding their nodal metastases
status. In the setting of gastric, colorectal, breast and
other neoplasms, promising data have been reported
[28–30]. Comparing to NR, which is a function of the
number of retrieved nodes, LODDS is a function of the
number of negative lymph nodes. In the setting of
pancreatic cancer, only one study has analyzed this par-
ameter, suggesting the advantage of LODDS over the NR
in node-negative patients [15]. Patients with pancreatic
cancer and portal vein/superior mesenteric vein axes in-
volvement represent a peculiar and challenging subset of
patients. Several questions are still open in this setting
regarding better perioperative treatment, surgical strat-
egies and prognostic stratification. No study has thus far
analyzed the nodal staging system in this subset of
patients to our knowledge, and for these reasons we
reviewed a multicenter database to report our data about
nodal prognostic factors in patients with venous
invasion.
Our study analyzed a population of 303 patients
undergoing pancreatectomy combined with venous
resection. Patients were treated in referral centers for
pancreatic pathology, and standard lymphadenectomy,
as recommended by the ISGPS, was performed. The
mean number of retrieved lymph nodes was high (33.5),
and the majority of patients (70.6%) had at least one
metastatic node. Patients submitted to LP had a higher
number of retrieved nodes, whereas the number of
metastatic nodes was not different in patients
Table 4 Multivariate analyses using the Cox proportional hazard
method. Evaluation of prognostic impact of number of
metastatic nodes, pN, nodal ratio and LODDS
Variable b SE P Exp (b) 95% CI
Age −0.100 0.184 0.585 0.905 0.633 to 1.294
Sex −0.244 0.188 0.196 0.784 0.543 to 1.132
Tumor size 0.176 0.197 0.372 1.192 0.813 to 1.749
R status −0.089 0.221 0.686 0.915 0.594 to 1.407
T stage −0.059 0.193 0.759 0.942 0.646 to 1.374
N. met. Nodes 0.427 0.186 0.022 1.533 1.066 to 2.23
Age −0.013 0.183 0.945 0.987 0.691 to 1.411
Sex −0.247 0.189 0.192 0.781 0.540 to 1.130
Tumor size 0.190 0.197 0.336 1.209 0.823 to 1.775
R status −0.085 0.218 0.698 0.919 0.600 to 1.407
T stage −0.115 0.195 0.555 0.892 0.610 to 1.303
N stage 0.603 0.239 0.011 1.828 1.148 to 2.911
Age −0.0812 0.183 0.655 0.922 0.646 to 1.316
Sex −0.195 0.190 0.305 0.823 0.568 to 1.192
Tumor size 0.206 0.196 0.293 1.229 0.838 to 1.803
R status −0.170 0.221 0.441 0.843 0.548 to 1.298
T stage −0.019 0.188 0.920 0.981 0.680 to 1.416
Nodal ratio 0.384 0.108 0.001 1.468 1.189 to 1.811
Age −0.010 0.183 0.955 0.989 0.692 to 1.415
Sex −0.229 0.188 0.221 0.795 0.551 to 1.146
Tumor size 0.184 0.197 0.349 1.202 0.819 to 1.764
R status −0.189 0.222 0.395 0.828 0.537 to 1.277
T stage −0.114 0.197 0.563 0.892 0.608 to 1.310
LODDS 0.273 0.089 0.002 1.313 1.105 to 1.562
N. met. Nodes number of metastatic nodes, NR nodal ratio, LODDS log odds of
positive lymph nodes
Fig. 5 Comparison of ROC curves analysis between the number of
metastatic nodes, pN status, the NR and LODDS
Fig. 6 Relationship between LODDS and the NR
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undergoing PD, LP or TP. Univariate and multivariate
analyses of prognostic factors were performed. Nodal
staging indexes were significant predictors of survival,
and the multivariate analysis confirmed the significant
prognostic value of the number of metastatic nodes,
pN, the NR, and LODDS. A comparison of the differ-
ent systems was attempted to demonstrate the super-
iority of one of them. The ROC curves’ comparison
did not show any significant differences. LODDS had
a lower and non-significant correlation with the num-
ber of retrieved nodes according to the Pearson test,
which may be advantageous in the case of inadequate
lymphadenectomy (in this series, only 12.5% of pa-
tients has fewer than 11 retrieved nodes). A scatter
plot was presented to show that LODDS has the
power to discriminate patients with the same NR (0
or 1) but a different prognosis. However, in the entire
cohort, all nodal staging systems seemed to be effica-
cious with a strong prognostic significance.
We further studied the group of patients having at
least one nodal metastasis. Clearly, pN classification is
limited in this setting, because all patients are classified
as N1. The comparison of survival curves via the log-
rank test demonstrated that the NR, the number of posi-
tive nodes and LODDS might all provide further
stratification for these patients. This result is concordant
with those of previous studies, and confirms that pN sta-
ging may also be integrated by further information. The
number of positive nodes is easy to retrieve and does
not require calculation. However, patients with different
prognosis may have the same values. For example, the
number of positive nodes is the same for patients having
4 metastatic nodes out of 4 retrieved (100% of metastatic
nodes) or 4 out of 40 (10%), for example. The NR is sim-
ple to calculate. NR carries information that are related
to both the number of metastatic and retrieved nodes.
However, for values approaching 1 its accuracy seems to
diminish (no difference between a patient with 1/1 me-
tastasis and one with 40/40). Furthermore, further strati-
fication of N0 patients is not possible using NR and
number of positive nodes. LODDS represent a nodal
prognostic index, which is more complex to understand.
Furthermore, calculation is less simple, which explain
why is rarely used in clinical practice. Theoretically,
LODDS have several advantages, including the possibil-
ity to further stratify N0 patients. In our series, we failed
to demonstrate a statistically significant difference in the
89 N0 patients using LODDS, but these results were
limited by the sample size of N0 patients in our study
population.
The novelty of this study is that it is the first one evalu-
ating different nodal staging systems in the setting of pa-
tients undergoing pancreatectomy with synchronous
venous resection. Patients with portal vein or superior
mesenteric vein invasion represent a challenging subset of
patients, and optimal prognostic stratification is needed in
their clinical management. We demonstrated that N1
patients might be further classified using the number
of examined lymph nodes, the NR and LODDS. Fur-
thermore, our study adds useful information on the
role of LODDS and pancreatic cancer, which is still
controversial. Only a few studies have been published
about LODDS in pancreatic cancer staging, with some
authors suggesting its utility [15] and others recom-
mending avoiding its use [31].
We point out some limitations of this study. Data
regarding disease-free survival were not analyzed, be-
cause not all included centres reported the information.
Furthermore, the study is retrospective. However, use of
ISGPS definition and the numbers of included patients
represent some remarkable aspects of this series. In this
study, neoadjuvant therapy was administered only to a
minority of patients. We can explain this data analyzing
NCCN guidelines until 2014. Up-front surgery was indi-
cated in fit patients with venous invasion at CT scan
suitable to resection and reconstruction with complete
tumor clearance. Furthermore, neoadjuvant therapy is a
factor that may modify nodal status; hence, the low rate
of neoadjuvant therapy in this study represents an
Table 5 Pearson correlation test between number of retrieved
lymph nodes and number of metastatic nodes, N status, NR,
LODDS
Correlation between of retrieved lymph nodes and number or
metastatic nodes
Sample size 303
Correlation coefficient r 0.298
Significance level p < 0.0001
95% coefficient interval for r 0.192 to 0.398
Correlation between of retrieved lymph nodes and N status
Sample size 303
Correlation coefficient r 0.1276
Significance level p = 0.026
95% coefficient interval for r 0.015 to 0.237
Correlation between of retrieved lymph nodes and N ratio
Sample size 303
Correlation coefficient r −0.193
Significance level p = 0.001
95% coefficient interval for r −0.299 to −0.082
Correlation between of retrieved lymph nodes and LODDS
Sample size 303
Correlation coefficient r −0.082
Significance level p = 0.154
95% coefficient interval for r −0.193 to 0.031
NR nodal ratio, LODDS log odds of positive lymph nodes
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advantage regarding the analysis of nodal prognostic
factors.
Conclusions
In conclusion, in patients undergoing pancreatectomy
with combined PV/SMV resection for pancreatic cancer,
the number of examined lymph nodes, the NR and
LODDS are useful for the further prognostic stratifica-
tion of N1 patients. All these staging systems permit the
better stratification of patients with nodal metastases
and are useful in clinical practice. No superiority of one
over the others was detected in patients undergoing pan-
createctomy with venous resection.
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